Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
NCT00828841
Completed
This study is testing the investigational drug, cetuximab, in combination with different chemotherapy drugs for lung cancer. The aim of the study is to determine which of the drug combinations looks most promising and should be tested further. The study will also look at what side effects may occur.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2013
Locations: Not set, Anniston, Alabama +83 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
NCT00147537
Completed
Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when administered with paclitaxel, carboplatin and erlotinib. Phase 2: To test the efficacy of CP-751,871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2013
Locations: Pfizer Investigational Site, Tucson, Arizona +30 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00009750
Unknown
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy and chemotherapy with peripheral stem cell transplantation may be an effective treatment for metastatic prostate cancer. PURPOSE: Phase I trial to study the effectiveness of monoclonal ant... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/19/2013
Locations: University of California Davis Cancer Center, Sacramento, California
Conditions: Prostate Cancer
Register for Updates
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer
NCT00004097
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have advanced and/or recurrent head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2013
Locations: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois +1 locations
Conditions: Head and Neck Cancer
Register for Updates
Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer
NCT00009763
Unknown
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with cyclosporine and paclitaxel may be an effective treatment for metastatic breast cancer. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy, cyclosporine, and paclitaxel in treating patients who have recurrent or refractory metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2013
Locations: University of California Davis Cancer Center, Sacramento, California
Conditions: Breast Cancer
Register for Updates
Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
NCT00009776
Unknown
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with cyclosporine and paclitaxel may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy combined with paclitaxel and cyclosporine in treating patients who have recurrent or refractory non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2013
Locations: University of California Davis Cancer Center, Sacramento, California
Conditions: Lymphoma
Register for Updates
Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer
NCT00138151
Terminated
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sometimes when chemotherapy is given, it does not stop the growth of tumor cells. The tumor is said to be resistant to chemotherapy. Giving isotretinoin and interferon alpha-2b together with paclitaxel may reduce drug resistance and allow the tumor cells to be killed. PURPOSE: This phase II trial is studying how well... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/17/2013
Locations: Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey +5 locations
Conditions: Cervical Cancer
Register for Updates
Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer
NCT00392392
Completed
This trial combines trastuzumab and bevacizumab monoclonal antibodies, with ABI-007 and carboplatin, as neoadjuvant therapy in previously untreated locally advanced breast cancers demonstrating HER2 gene amplification. It is hoped that this novel combination will result in increased pathologic response rates that will translate into long term outcome improvements in HER2 positive patients with locally advanced breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/17/2013
Locations: Florida Cancer Specialists, Fort Myers, Florida +5 locations
Conditions: Breast Cancer
Register for Updates
Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00024310
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Folic acid may protect normal cells from the side effects of chemotherapy and may increase the effectiveness of chemotherapy by making tumor cells more sensitive to the drug. Lometrexol may stop the growth of tumors by blocking one of the enzymes necessary for cancer cell growth. Combining chemotherapy with folic acid and lometrexol may kill more tumor cells. PURPOSE: Phase I... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2013
Locations: Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California
Conditions: Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer
NCT00983424
Completed
The purpose of this research study is to evaluate the safety of therapy with nab-paclitaxel and CsA and if the addition of Cyclosporine A (CsA) to nab-paclitaxel helps stop cancer cells as well as or better than nab-paclitaxel alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2013
Locations: Northwestern University, Northwestern Medical Faculty Foundation, Chicago, Illinois
Conditions: Metastatic Breast Cancer
Register for Updates
A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
NCT00970580
Completed
The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2013
Locations: Resesarch Site, Los Angeles, California +2 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer
NCT00002939
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan and paclitaxel in treating patients with metastatic or recurrent cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/04/2013
Locations: University of Chicago Cancer Research Center, Chicago, Illinois
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates